Three Major U.S. Sites Secured for Polyrizon's NASARIX™ Allergy Blocker Trial
PLRZ has more than doubled off its 52-week low of $2.88.
Summary
Polyrizon has secured agreements with three major U.S. clinical sites for its NASARIX™ (PL-14) trial, an intranasal hydrogel for seasonal allergic rhinitis. These sites are crucial for efficient patient enrollment and represent significant progress towards initiating the multi-center study. For a development-stage biotech, advancing a lead product into clinical trials is a key de-risking event. This follows recent financing activities, including a $3.5 million offering in April. Investors will watch for the official trial initiation and further site additions.
At the time of this announcement, PLRZ was trading at $12.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.2M. The 52-week trading range was $2.88 to $18.20. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.